Conflicts of interest in dermatology

Acta Dermato-Venereologica

Volumn 86, Issue 6, 2006, Pages 485-497

  Williams, Hywel C ^a   Naldi, Luigi ^b   Paul, Carle ^c   Vahlquist, Anders ^d   Schroter, Sara ^e   Jobling, Ray ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b OSPEDALI RIUNITI   (Italy)

^c CHU PURPAN   (France)

^d UPPSALA UNIVERSITY   (Sweden)

^e St John's College ^*

Author keywords

Conflicts of interest; Dermatology; Disease awareness campaigns; Disease mongering; Ghost authorship

Indexed keywords

ARTICLE; CONFLICT OF INTEREST; DRUG INDUSTRY; HEALTH SERVICE; MEDICAL RESEARCH; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PROFIT; PUBLICATION; WRITING;

AUTHORSHIP; CLINICAL TRIALS; CONFLICT OF INTEREST; DERMATOLOGY; DRUG INDUSTRY; HUMANS; PUBLISHING; RESEARCH SUPPORT;

EID: 33845620654     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0191     Document Type: Article

References (59)

1. Bartus CL, Katz KA. Advertising in dermatology Journals: journals' and journal editors' policies, practices, and attitudes. J Am Acad Dermatol 2006; 55: 116-122.
2. Goldsmith LA. Conflict of interest and the JID. J Invest Dermatol 2006; 126: 1-2.
3. Perlis CS, Harwood M, Perlis RH. Extent and impact of industry sponsorship conflicts of interest in dermatology research. J Am Acad Dermatol 2005; 52: 967-971.
4. Prendergast MM, Abramovits W, Boguniewicz M, Lebwohl M, Tokar M, Tong KB. Look beyond financial conflicts of interest in evaluating industry-academia collaborations in burden-of-illness and outcomes research studies in dermatology. J Invest Dermatol 2004; 123: 452-454.
5. Eedy DJ, Graham-Brown RA. Ethics and conflicts of interest in the BJD. Br J Dermatol 2004; 151: 1-2.
6. Brunne V, Mertins G, Reimann G, Brockmeyer NH. Off-label use in dermatological practice. The conflict between professional duty and legal requirements) Hautarzt 2004; 55: 727-734.
7. Sams WM, Freedberg IM. The dermatology-industry interface: defining the boundaries. J Am Acad Dermatol 2000; 43: 550-554.
8. Blank IH. Industry-funded dermatologic research within academia in the United States: fiscal and ethical considerations. J Invest Dermatol 1992; 98: 265-268.
9. th 2006).
10. Landefeld CS, Chren MM. Drug companies and information about drugs: recommendations for doctors. Characteristics of materials distributed by drug companies: four points of view. J Gen Intern Med 1996; 11: 642-644.
11. Chren MM. Interactions between physicians and drug company representatives. Am J Med 1999; 107: 182-183.
12. Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 2006; 295: 429-433.
13. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000; 283: 373-380.
14. Mullis K. Dancing naked in the mind field. New York: Pantheon Books, 1998.
15. Horton R. The dawn of McScience. New York Rev Books 2004; 514: 7-9.
16. Angell M. The truth about drug companies: how they deceive us and what to do about it. New York: Random House, 2005: 336.
17. Kassirer JP. On the take: how medicine's complicity with big business can endanger your health. New York: Oxford University Press 2004: 251.
18. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005; 2: 138. Epub 2005 May 17.
19. Naldi L, Svensson A, Diepgen T, Elsner P, Grob JJ, Coenraads PJ, et al. European Dermato-Epidemiology Network. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003; 120: 738-741.
20. Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, et al. Study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994; 154: 157-163.
21. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality. BMJ 2003; 326: 1167-1170.
22. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003; 326: 1171-1173.
23. Naldi L. A new era in the management of psoriasis? Promises and facts. Dermatology 2005; 210: 179-181.
24. http://www.worldpsoriasisday.com/1_history/index.html
25. www.psocare.it
26. Liberati A, Magrini N. Information from drug companies and opinion leaders. BMJ 2003; 326: 1156-1157.
27. Garattini S, Bertele' V, Li Bassi L. Light and shade in proposed revision of EU drug-regulatory legislation. Lancet 2003; 361: 635-636.
28. Gross CP, Gupta AR, Krumholz HM. Disclosure of financial competing interests in randomised controlled trials: cross sectional review. BMJ 2003; 326: 526-527.
29. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125: 1020-1025.
30. Pediatric Advisory Committee of the Food and Drugs Administration. Washington DC February 2005. Transcripts of the meeting. Available from: www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4089T2.pdf
31. Experimental lotion repairs sun damage. ABC news, May 2003. Available from: http://www.agiderm.com
32. International Committee of Medical Journal Editors criteria for authorship. Available from: http://www.icmje.org/
33. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 2004; 38: 579-585.
34. Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. N Engl J Med 2002; 342: 1539-1544.
35. Lemens T. Confronting the conflict of interest crisis in medical research. Monash Bioethics Review 2004; 23: 19-40.
36. Alefacept package insert. Available at: www.fda.gov/medwaTCH/SAFETY/2005/ Amevive_PI.pdf.
37. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular Alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-727.
38. Lipton S, Boyd EA, Bero LA. Conflicts of interest in academic research: policies, processes and attitudes. Accountability in Research 2004; 11: 83-102.
39. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. Writing and editing for biomedical publication. JAMA 1997; 277: 927-934.
40. Wechsler AD. Conflict of interest: what's a journal to do? (Editorial). J Thoracic Cardiovasc Surg 2006; 131: 771-772.
41. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in BMJ. BMJ 2002; 325: 249-252.
42. Als-Nielson B, Chen W, Gluud C, Kajegard LL. Association of funding and conclusions in randomised drug trials. JAMA 2003; 290: 291-298.
43. Chaudhry S, Schroter S, Smith R, Morris J. Does declaration of competing interests affect reader perceptions: a randomised trial? BMJ 2002; 325: 1391-1392.
44. Schroter S, Morris J, Chaudhry S, Smith, R, Barratt H. Does the type of competing interest statement affect reader perceptions of the credibility of research? A randomised trial. BMJ 2004; 328: 742-743.
45. Coles R, Jobling R. Psoriasis associations. In: Roenigk HH, Maibach HI, editors. Psoriasis. New York: Marcel Dekker, 1985.
46. Herxheimer A. Relationships between the pharmaceutical industry and patients' organisations. BMJ 2003; 326: 1208-1210.
47. HAI Europe, The ties that bind. Paris: HAI Europe, 1998 (see also www.haiweb.org).
48. Which? magazine, Who's injecting the cash? 24 April 2003.
49. th Report on the Influence of the Pharmaceutical Industry - Section 8: Disease Awareness Campaigns. HC42-I, 2005.
50. Consumers International. Branding the cure: a consumer perspective on corporate social responsibility, drug promotion, & the pharmaceutical industry. London: Consumers International, 2006.
51. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002; 324: 886-891.
52. Moynihan R. US seniors group attacks pharmaceutical industry "fronts". BMJ 2003; 326: 351.
53. Wang L-N. New ways to ensure patient loyalty. The Pharmaceutical Journal 2004; 272: 635-636.
54. EUROPSO. Report on Operations, 2001-2004.
55. Oral presentation of the Report on Operation, 2001-2004.
56. Williams H, Goldsmith L. The JID opens its doors to high-quality randomized controlled clinical trials. J Invest Dermatol 2006; 126: 1683-1684.
57. Ormerod AD, Williams HC. Compulsory registration of trials. Br J Dermatol 2005; 152: 859-860.
58. Cox N, Williams HC. Can you COPE with CONSORT? Br J Dermatol 2000; 142: 1-7.
59. Collier A, Johnson CR, Delamere F, Leonard T, Dellavalle RP, Williams H. The Cochrane Skin Group: promoting the best evidence. Journal of Cutaneous Medicine and Surgery 2005; 9: 324-331.